These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34397495)

  • 21. Sulfasalazine-induced hypersensitivity: a case report of DRESS syndrome.
    Yeşilova Z; Kantarcioğlu M; Erçin CN; Safalioğlu M; Kilciler G; Koç E; Atli M; Uygun A
    Turk J Gastroenterol; 2009 Dec; 20(4):298-9. PubMed ID: 20084578
    [No Abstract]   [Full Text] [Related]  

  • 22. Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.
    Khattak FH; Morris IM; Mattingly PC
    Br J Rheumatol; 1996 Jan; 35(1):104. PubMed ID: 8624617
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe drug-induced blistering disorders.
    Roujeau JC
    Rev Rhum Engl Ed; 1997 Jan; 64(1):5-9. PubMed ID: 9051853
    [No Abstract]   [Full Text] [Related]  

  • 24. [A case of salazosulfapyridine induced hypersensitivity syndrome].
    Orita M; Katakura Y; Kobayashi M; Ishii T; Watanabe Y; Yotsuyanagi H; Suzuki M; Itoh F
    Nihon Shokakibyo Gakkai Zasshi; 2005 May; 102(5):600-4. PubMed ID: 15920959
    [No Abstract]   [Full Text] [Related]  

  • 25. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis.
    Hassikou H; El Haouri M; Tabache F; Baaj M; Safi S; Hadri L
    Joint Bone Spine; 2008 Oct; 75(5):597-9. PubMed ID: 18805724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
    Soejima M; Kawaguchi Y; Hara M; Kamatani N
    J Rheumatol; 2008 Apr; 35(4):724. PubMed ID: 18398952
    [No Abstract]   [Full Text] [Related]  

  • 28. Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.
    Quallich LG; Greenson J; Haftel HM; Fontana RJ
    BMC Gastroenterol; 2001; 1():8. PubMed ID: 11570976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient.
    Sagnelli C; Gentile V; Tirri R; Macera M; Cappabianca S; Ciccia F; Coppola N;
    J Infect; 2020 Dec; 81(6):979-997. PubMed ID: 32474034
    [No Abstract]   [Full Text] [Related]  

  • 30. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.
    Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J
    Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug rash with eosinophilia and systemic symptoms syndrome induced by sulfasalazine.
    Bahat G; Celik HG; Tufan F; Saka B
    Joint Bone Spine; 2010 Jan; 77(1):87-8. PubMed ID: 19854669
    [No Abstract]   [Full Text] [Related]  

  • 32. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
    Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC;
    Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facts, not Fear: Safety of Hydroxychloroquine.
    Kuraitis D; Murina A
    Am J Med Sci; 2020 Aug; 360(2):199-200. PubMed ID: 32560964
    [No Abstract]   [Full Text] [Related]  

  • 34. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy.
    Fallon MJ; Heck JN
    J Oncol Pharm Pract; 2015 Oct; 21(5):388-92. PubMed ID: 25005569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy.
    Klein SM; Khan MA
    J Rheumatol; 1983 Jun; 10(3):512-3. PubMed ID: 6224935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease.
    Borg AA
    Br J Rheumatol; 1995 Nov; 34(11):1097-8. PubMed ID: 8542218
    [No Abstract]   [Full Text] [Related]  

  • 37. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: A case report.
    Emadi SN; Hamzelou S; Saffarian Z; Shakoei S
    Dermatol Ther; 2021 Jan; 34(1):e14656. PubMed ID: 33301196
    [No Abstract]   [Full Text] [Related]  

  • 38. Cyclosporin for sulphasalazine-induced aplastic anaemia in a patient with early rheumatoid arthritis.
    Nurmohamed MT; Soesan M; van Oers MH; Dijkmans BA; van Soesbergen RM
    Rheumatology (Oxford); 2000 Dec; 39(12):1431-3. PubMed ID: 11136894
    [No Abstract]   [Full Text] [Related]  

  • 39. Toxic epidermal necrolysis in a child with lupus-associated pancreatitis.
    Marija S; Ivana B; Nina R; Dragan N; Zlatko B; Branislav J; Jelena P; Dusica S
    Rheumatol Int; 2017 Jul; 37(7):1221-1226. PubMed ID: 28239770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
    Cai S; Sun W; Li M; Dong L
    Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.